Inhaled Aminoglycosides

Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract Agents in this class—most notably inhaled tobramycin and inhaled liposomal amikacin—are primarily indicated for the management of chronic pulmonary infections, including *Pseudomonas aeruginosa* airway colonization in cystic fibrosis and refractory *Mycobacterium avium* complex lung disease

Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity

Inhaled aminoglycosides are a targeted route-specific subcategory of aminoglycoside antibacterial drugs formulated for aerosol or dry-powder administration directly into the respiratory tract They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity Agents in this class—most notably in...

They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity

They exert bactericidal activity by binding to the bacterial 30S ribosomal subunit to disrupt protein synthesis, delivering high local drug concentrations directly to the endobronchial space while limiting systemic absorption and associated nephrotoxicity and ototoxicity

Agents in this class—most notably inhaled tobramycin and inhaled liposomal amikacin—are primarily indicated for the management of chronic pulmonary infections, including *Pseudomonas aeruginosa* airway colonization in cystic fibrosis and refractory *Mycobacterium avium* complex lung disease